154 related articles for article (PubMed ID: 36892631)
21. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
[TBL] [Abstract][Full Text] [Related]
22. Uses of pharmacovigilance databases: An overview.
Bihan K; Lebrun-Vignes B; Funck-Brentano C; Salem JE
Therapie; 2020; 75(6):591-598. PubMed ID: 32169289
[TBL] [Abstract][Full Text] [Related]
23. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database.
Chen X; Wei L; Chi L; Guo X; Chen C; Guo Z; Liang J; Zheng Y; He J; Ye X
Br J Clin Pharmacol; 2022 May; 88(5):2180-2189. PubMed ID: 34786743
[TBL] [Abstract][Full Text] [Related]
24. Risk of appendicitis associated with the use of clozapine: A pharmacovigilance study.
Uwai Y; Nabekura T
Asian J Psychiatr; 2022 Nov; 77():103264. PubMed ID: 36150349
[No Abstract] [Full Text] [Related]
25. Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database.
Mettler C; Chouchana L; Terrier B
J Rheumatol; 2020 Aug; 47(8):1298-1300. PubMed ID: 32482651
[No Abstract] [Full Text] [Related]
26. Pharmacovigilance activities in ASEAN countries.
Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
[TBL] [Abstract][Full Text] [Related]
27. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
[TBL] [Abstract][Full Text] [Related]
28. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.
Danton AC; Montastruc F; Sommet A; Durrieu G; Bagheri H; Bondon-Guitton E; Lapeyre-Mestre M; Montastruc JL
Eur J Clin Pharmacol; 2013 Apr; 69(4):885-8. PubMed ID: 22996074
[TBL] [Abstract][Full Text] [Related]
29. Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance.
Basch E
Drug Saf; 2013 Apr; 36(4):277-8. PubMed ID: 23508543
[No Abstract] [Full Text] [Related]
30. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
[TBL] [Abstract][Full Text] [Related]
31. The value of case reports in pharmacovigilance.
Garcia-Doval I; Segovia E; Hunter H; Frew J; Naldi L
Br J Dermatol; 2020 Nov; 183(5):795-796. PubMed ID: 33135791
[No Abstract] [Full Text] [Related]
32. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.
Khouri C; Petit C; Tod M; Lepelley M; Revol B; Roustit M; Cracowski JL
J Clin Epidemiol; 2021 Jun; 134():14-21. PubMed ID: 33508405
[TBL] [Abstract][Full Text] [Related]
33. Adverse drug reactions in neonates: could we be documenting more?
Hawcutt DB; O'Connor O; Turner MA
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
[TBL] [Abstract][Full Text] [Related]
34. Pharmacovigilance: methods, recent developments and future perspectives.
Härmark L; van Grootheest AC
Eur J Clin Pharmacol; 2008 Aug; 64(8):743-52. PubMed ID: 18523760
[TBL] [Abstract][Full Text] [Related]
35. Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance database.
Khouri C; Revol B; Lepelley M; Mallaret M; Cracowski JL
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1427-1428. PubMed ID: 30379373
[No Abstract] [Full Text] [Related]
36. The futility of adverse drug event reporting systems for monitoring known safety issues: A case study of myocardial infarction with rofecoxib and other drugs.
Haguinet F; Bate A; Stegmann JU
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5719. PubMed ID: 37867313
[No Abstract] [Full Text] [Related]
37. CPCSSN's role in improving pharmacovigilance.
Williamson T; Lévesque L; Morkem R; Birtwhistle R
Can Fam Physician; 2014 Jul; 60(7):678-80. PubMed ID: 25022644
[No Abstract] [Full Text] [Related]
38. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
39. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
40. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
Cliff-Eribo KO; Sammons H; Choonara I
Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
